12 results
S-1
EX-4.2
GLTO
Galecto Inc
7 Oct 20
IPO registration
5:01pm
Agreement as of the date first written above.
INVESTORS:
Janus Henderson Biotech Innovation Master Fund Limited
By: Janus Capital Management LLC, its … .
OrbiMed Genesis Master Fund, L.P.
The Biotech Growth Trust PLC
JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED
JANUS HENDERSON CAPITAL FUNDS
S-1/A
EX-4.2
GLTO
Galecto Inc
22 Oct 20
IPO registration (amended)
6:13am
as of the date first written above.
INVESTORS:
Janus Henderson Biotech Innovation Master Fund Limited
By: Janus Capital Management LLC, its investment advisor … Trust PLC
JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED
JANUS HENDERSON CAPITAL FUNDS PLC ON BEHALF OF ITS SERIES JANUS HENDERSON GLOBAL LIFE
DEF 14A
GLTO
Galecto Inc
14 Apr 21
Definitive proxy
7:00am
in Innovation and Entrepreneurship.
Jonathan Freve has served as our Chief Financial Officer since April 2020. Prior to joining us, Mr. Freve served as Chief
S-1/A
GLTO
Galecto Inc
22 Oct 20
IPO registration (amended)
6:13am
innovation, or if its authorization would be in the interest of public health in the EEA. Under the centralized procedure, the maximum timeframe … the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days
DRS
m93ts64 uf
2 Sep 20
Draft registration statement
12:00am
S-1
9qbwabgpr8nxjgsh1
7 Oct 20
IPO registration
5:01pm
424B4
726f5moe4ayo
30 Oct 20
Prospectus supplement with pricing info
4:31pm
10-K
xie6wmd e4
29 Mar 21
Annual report
6:03am
- Prev
- 1
- Next